Which medications in the drug class Monoclonal Antibodies are used in the treatment of Hemophilia A?

Updated: Apr 08, 2020
  • Author: Douglass A Drelich, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print

Monoclonal Antibodies

Monoclonal antibodies are used to bind to one specific substance in the body (eg, molecules, antigens). This binding is very versatile and can mimic, block, or cause changes to enact precise mechanisms (eg, bridging molecules, replacing or activating enzymes or cofactors, immune system stimulation).

Emicizumab (Hemlibra, emicizumab-kxwh)

Emicizumab is a first-in-class bispecific monoclonal antibody that bridges activated FIX and FX to restore the function of activated FVIII. It is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (including newborns) with hemophilia A with or without factor VIII inhibitors.

Rituximab (Rituxan)

Rituximab is a monoclonal antibody directed against the CD20 antigen on B-lymphocytes. It is recommended as second-line therapy in immune tolerance induction regimens for patients with FVIII inhibitors, especially those with high inhibitor titers. This agent binds to, and mediates destruction of, B-cells, thereby decreasing production of FVIII inhibitors and autoimmunization.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!